36476-86-5

Basic information

• Product Name: 1-Benzhydrylazetane-3-carbonitrile
• Synonyms: 3-CYANO-1-(DIPHENYLMETHYL)AZETIDINE;1-BENZHYDRYLAZETANE-3-CARBONITRILE;1-BENZHYDRYL-AZETIDINE-3-CARBONITRILE;1-BENZHYDRYL-3-CYANOAZETIDINE;BUTTPARK 37\04-15;1-BENZHYDRYL-3-CYANOAZETIDINE 98%;1-(Diphenylmethyl)-3-azetidinecarbonitrile;1-(diphenylmethyl)azetidine-3-carbonitrile
• CAS NO: 36476-86-5
• Molecular Formula: C₁₇H₁₆N₂
• Molecular Weight: 248.32
• Product Categories: Azetidine;Aromatics;Heterocycles
• Mol File: 36476-86-5.mol

Chemical Properties

• Melting Point: 150-153°C
• Boiling Point: 384.3 °C at 760 mmHg
• Flash Point: 164 °C
• Appearance: /Solid
• Density: 1.15 g/cm³
• Vapor Pressure: 4.14E-06mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: Room temperature.
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 5.61±0.10(Predicted)
• Stability: Good
• CAS DataBase Reference: 1-Benzhydrylazetane-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzhydrylazetane-3-carbonitrile(36476-86-5)
• EPA Substance Registry System: 1-Benzhydrylazetane-3-carbonitrile(36476-86-5)

Safety Data

• Hazard Codes: C
• Statements: 20/21/22-36/37/38-34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3276
• HazardClass: IRRITANT
• Hazardous Substances Data: 36476-86-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C17H16N2/c18-11-14-12-19(13-14)17(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-10,14,17H,12-13H2

Upstream product

• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 143-33-9 sodium cyanide 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 773837-37-9 sodium cyanide 
• 91-00-9 Benzhydrylamine 

Downstream Products

• 36476-88-7 3-(aminomethyl)-1-(1,1-diphenylmethyl)azetidine 
• 852655-67-5 1-(1-benzhydryl-azetidin-3-yl)-cyclopropylamine 
• 36476-87-6 1-benzhydrylazetidine-3-carboxylic acid 
• 53871-06-0 1-(diphenylmethyl)-3-methoxycarbonylazetidine 
• 345954-83-8 azetidine-3-carbonitrile hydrochloride 
• 1257260-54-0 C₂₃H₂₀FNO 
• 1257260-55-1 C₂₃H₁₉F₂NO 
• 72351-36-1 1-diphenylmethyl-3-hydroxymethylazetidine 
• 1351078-34-6 C₂₅H₃₈N₂O₆P₂ 
• 1391919-91-7 1-benzhydrylazetidin-3-carboxamide 
• 1416149-29-5 1-benzhydryl-3-(3-chloropyridin-4-yl)azetidine-3-carbonitrile 
• 1357614-76-6 1-benzhydryl-3-(2-bromo-4-(diethoxymethyl)phenyl)azetidine-3-carbonitrile 

Relevant articles and documents

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders

To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.

A practical and cost-efficient, one-pot conversion of aldehydes into nitriles mediated by 'activated DMSO'

Participation of activated DMSO in the one-pot transformation of aldehydes to nitriles has been described by reacting aldehydes with NHHHCl in DMSO in the absence of any added base or catalyst. The method is applicable to access a wide range of aromatic, heterocyclic, and aliphatic nitriles, in which only water is a byproduct. A straightforward and practical procedure is demonstrated on a multigram scale. Georg Thieme Verlag Stuttgart - New York.

AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).]

PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE

A pyridine or pyrimidine derivative represented by the formula (I) has an excellent HGFR inhibitory activity and exhibits strong cell proliferation inhibitory effect and anti-tumor effect against cancer cell lines with amplified HGFR gene. wherein R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen.

NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]

Azetidine derivatives, their preparation and pharmaceutical compositions containing them

Compounds of formula: in which R represents a CR1R2, C═C(R5)SO2R6 or C═C(R7)SO2alk radical, their preparation and the pharmaceutical compositions containing them.

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1

7-Azetidinylquinolones as antibacterial agents. Synthesis and structure- activity relationships

A series of novel antibacterial quinolones and naphthyridones has been prepared which contain 7-azetidinyl substituents in place of the usual piperazine or aminopyrrolidine groups. These azetidinyl derivatives were evaluated for in vitro activity by deter

Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents

Methods of treating cardiac arrhythmias and convulsions in warm-blooded animas and pharmaceutical compositions therefor are disclosed. The compounds useful in the methods of treatment and compositions are represented by the formula STR1 where n is 0 to 3 and R is H, C1 -C4 alkyl or arylalkyl and Ar is phenyl or substituted phenyl.